Organon & Co. (OGN): Long-Term Debt
$8.64B
As of 2025-12-31
$8.55B
As of 2026-06-30
-1.0%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.64B | -2.7% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $8.88B | +1.4% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $8.76B | -1.7% | 2025-11-10, Balance as of period end |
| 2022-12-31 | $8.91B | -2.4% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $9.13B | n/a | 2023-02-27, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $8.64B | -2.7% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $836.37M | n/a |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $3.76B | -12.9% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $5.36B | -12.3% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $20.82B | -3.7% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $2.57B | +7.8% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $8.95B | +17.6% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $828.97M | n/a |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $993.95M | +0.2% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗